The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I study of milademetan in combination with quizartinib in patients (pts) with newly diagnosed (ND) or relapsed/refractory (R/R) FLT3-ITD acute myeloid leukemia (AML).
 
Naval Guastad Daver
Consulting or Advisory Role - Abbvie; Agios; Astellas Pharma; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Jazz Pharmaceuticals; Novartis; Pfizer
Research Funding - Abbvie; Astellas Pharma; Bristol-Myers Squibb; Daiichi Sankyo; Genentech; Immunogen; Nohla Therapeutics; Pfizer; Servier
 
Weiguo Zhang
No Relationships to Disclose
 
Richard Graydon
Employment - Daiichi Sankyo
 
Vikas Dawra
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
 
Jingdong Xie
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Teva; Teva (I)
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Prasanna Kumar
Employment - Daiichi Sankyo
Stock and Other Ownership Interests - Daiichi Sankyo
Travel, Accommodations, Expenses - Daiichi Sankyo
 
Michael Andreeff
Stock and Other Ownership Interests - Aptose Biosciences; Eutropics; Oncoceutics; Oncolyze; Reata Pharmaceuticals; Senti Biosciences
Consulting or Advisory Role - Amgen; AstraZeneca; Celgene; Daiichi Sankyo; Jazz Pharmaceuticals
Research Funding - Amgen; AstraZeneca; Breast Cancer Research Foundation; CPRIT; Daiichi Sankyo; Karyopharm Therapeutics; NIH/NCI; Ono Pharmaceutical; United Therapeutics
Patents, Royalties, Other Intellectual Property - Patent with Reata
Travel, Accommodations, Expenses - Amgen; Aptose Biosciences; AstraZeneca; Oncoceutics